Display options
Cite
Grover S, Singla H, Chakrabarti S, et al. Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital. Indian J Psychol Med. 2020;42(2):162-167doi: 10.4103/IJPSYM.IJPSYM_269_19.
Grover, S., Singla, H., Chakrabarti, S., & Avasthi, A. (2020). Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital. Indian journal of psychological medicine, 42(2), 162-167. https://doi.org/10.4103/IJPSYM.IJPSYM_269_19
Grover, Sandeep, et al. "Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital." Indian journal of psychological medicine vol. 42,2 (2020): 162-167. doi: https://doi.org/10.4103/IJPSYM.IJPSYM_269_19
Grover S, Singla H, Chakrabarti S, Avasthi A. Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital. Indian J Psychol Med. 2020 Mar 09;42(2):162-167. doi: 10.4103/IJPSYM.IJPSYM_269_19. eCollection 2020. PMID: 32346258; PMCID: PMC7173656.
Copy Download .nbib Format: NLM
Share it on

Indian J Psychol Med. 2020 Mar 09;42(2):162-167. doi: 10.4103/IJPSYM.IJPSYM_269_19. eCollection 2020.

Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital.

Indian journal of psychological medicine

Sandeep Grover, Himanshu Singla, Subho Chakrabarti, Ajit Avasthi

Affiliations

  1. Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

PMID: 32346258 PMCID: PMC7173656 DOI: 10.4103/IJPSYM.IJPSYM_269_19

Abstract

BACKGROUND: Little is known from India about the experience of using olanzapine long-acting antipsychotic injectables (LAI). In this background, this study aimed to evaluate the clinical profile of patients suffering from schizophrenia who were prescribed olanzapine LAI and to evaluate the usefulness and acceptability of olanzapine LAI among these patients.

METHODS: In this retrospective study, data of all the patients with schizophrenia receiving olanzapine pamoate, was extracted.

RESULTS: 40 patients (males-55%; mean [SD] age- 36.2 (12) years; mean duration of illness (SD) prior to depot-143.3 (115.9) months) were included in the study. Olanzapine LAI was invariably prescribed in patients with a past history of non-compliance. Data was available for a mean (SD) follow-up duration of 17 (10.8) months. The most frequently used dose of olanzapine LAI used was 300 mg every two weeks (55%). This was followed by 405 mg every four weeks in (32.5%). Mean Clinical Global Impression (CGI) Severity score prior to starting of olanzapine LAI was 5.8 (0.7), which reduced to 2.7 (1.1) at the time of last follow-up or the last use of olanzapine LAI, and this was a statistically significant improvement (paired

CONCLUSION: Olanzapine LAI is mostly used in patients with a history of non-compliance. Olanzapine LAI is associated with a significant reduction in the severity of illness.

Copyright: © 2020 Indian Psychiatric Society - South Zonal Branch.

Keywords: Depot; Olanzapine LAI is mostly used in patients with a past history of poor compliance with oral antipsychotics. The use of Olanzapine LAI is associated with a significant reduction in psychopathology.; long-acting injectables; olanzapine

Conflict of interest statement

There are no conflicts of interest.

References

  1. BMC Psychiatry. 2010 Jun 10;10:43 - PubMed
  2. Br J Psychiatry Suppl. 1994 Nov;(25):18-21 - PubMed
  3. Ther Adv Psychopharmacol. 2013 Apr;3(2):89-99 - PubMed
  4. Psychol Med. 1992 Feb;22(1):131-45 - PubMed
  5. Ther Adv Psychopharmacol. 2014 Oct;4(5):186-92 - PubMed
  6. Am J Psychiatry. 2011 Jun;168(6):603-9 - PubMed
  7. Indian J Psychiatry. 2017 Oct-Dec;59(4):517-519 - PubMed
  8. Schizophr Bull. 2018 Apr 6;44(3):603-619 - PubMed
  9. Indian J Psychol Med. 2016 Jul-Aug;38(4):366-9 - PubMed
  10. Schizophr Bull. 1991;17(2):325-51 - PubMed
  11. Ther Adv Psychopharmacol. 2016 Oct;6(5):301-307 - PubMed
  12. N Engl J Med. 2005 Sep 22;353(12):1209-23 - PubMed
  13. BMC Psychiatry. 2010 Jun 10;10:45 - PubMed
  14. CNS Drugs. 2013 Aug;27(8):637-52 - PubMed
  15. J Clin Psychiatry. 2004 Apr;65(4):500-8 - PubMed
  16. Int Clin Psychopharmacol. 2014 Nov;29(6):322-31 - PubMed
  17. J Clin Psychiatry. 2002 Oct;63(10):892-909 - PubMed
  18. Clin Neuropharmacol. 2019 Mar/Apr;42(2):64-65 - PubMed
  19. CNS Drugs. 2016 Aug;30(8):689-701 - PubMed
  20. Schizophr Res. 2011 Apr;127(1-3):83-92 - PubMed
  21. J Clin Psychiatry. 2008 May;69(5):790-9 - PubMed
  22. Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56 - PubMed
  23. Br J Psychiatry. 2005 Jul;187:9-20 - PubMed
  24. Br J Psychiatry. 1984 May;144:475-81 - PubMed
  25. Curr Med Res Opin. 2007 Oct;23(10):2305-12 - PubMed
  26. Br J Psychiatry Suppl. 2009 Nov;52:S29-36 - PubMed
  27. Am J Psychiatry. 2010 Feb;167(2):181-9 - PubMed
  28. Neuropsychiatr Dis Treat. 2015 May 27;11:1349-57 - PubMed
  29. J Clin Psychiatry. 2003;64 Suppl 12:5-19 - PubMed
  30. Soc Psychiatry Psychiatr Epidemiol. 1996 Nov;31(6):349-54 - PubMed
  31. Schizophr Bull. 2010 Jan;36(1):71-93 - PubMed
  32. J Clin Psychopharmacol. 1998 Apr;18(2 Suppl 1):20S-4S - PubMed
  33. Psychiatr Serv. 2000 Feb;51(2):216-22 - PubMed
  34. Psychol Med Monogr Suppl. 1992;20:1-97 - PubMed

Publication Types